GlobalReach Health

September 16, 2021

Brukinsa Receives Two New Lymphoma Indications

September 16, 2021 – The U.S. FDA has approved two new indications for Brukinsa® (zanubrutinib), the first to treat adults who have Waldenström's macroglobulinemia